Uterine Elastography: a Potential Predictor of Embryo Transfer Success
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline Zuckerman, BS
- Phone Number: 19736562841
- Email: clinicalresearchteam@ivirma.com
Study Contact Backup
- Name: Christine V Whitehead, BSN, RN
- Phone Number: 19736562841
- Email: cwhitehead@ivirma.com
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Reproductive Medicine Associates of new Jersey
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patients, 18yo-45yo, presenting for ultrasound the day prior to embryo transfer
- Patients planning to undergo single embryo transfer (SET) of a euploid embryo by Preimplantation genetic testing for aneuploidy (PGT-A)
- Uterine evaluation prior to transfer (saline sonogram or hysteroscopy) within 1 year
- Egg recipients
Exclusion Criteria:
- Gestational carriers
- BMI > 35
- Diagnosis of a uterine anomaly
- History of uterine surgery, excluding polypectomy, c-section, D&C
- Communicating hydrosalpinx
- Transfer of an embryo of unknown ploidy status or embryos of undetermined safety
- Surgically retrieved sperm
- Embryos that were cryopreserved on day 7 of development
- Poor quality embryos defined by modified Gardner grading criteria used in the embryology lab
- Sonographically abnormal appearing uteri, including distortions from leiomyomas and thin endometrium
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Women undergoing euploid, single frozen embryo transfer
Women age 18yo-45yo undergoing euploid, single, frozen embryo transfer with sonographically normal appearing uterus without uterine factor infertility
|
Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sustained Implantation Rate
Time Frame: 6 weeks after embryo transfer
|
number of fetal heart beats at time of discharge ultrasound
|
6 weeks after embryo transfer
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chemical Pregnancy
Time Frame: 8-10 days after embryo transfer
|
Positive serum bHCG level
|
8-10 days after embryo transfer
|
|
Clinical Pregnancy
Time Frame: 2-4 weeks after embryo transfer
|
presence of gestational sac on ultrasound
|
2-4 weeks after embryo transfer
|
|
Clinical Pregnancy Loss
Time Frame: 2-40 weeks after embryo transfer
|
loss of gestational sac, yolk sac, fetal pole, fetal heart beat on ultrasound after being present
|
2-40 weeks after embryo transfer
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marie Werner, MD, Reproductive Medicine Associates of new Jersey
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RMA-2022-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.